Novel therapies for multiple myeloma.
Multiple myeloma (MM) continues to evade cure by conventional therapies, increasing the urgency for new, biologically based treatments. Reviewed in this discussion are novel chemotherapies under clinical trial that capitalize upon greater comprehension of tumor pathophysiology. In targeting tumor biology, these therapies serve as a model of treatment with great potential for improving outcomes in patients with MM.
Ryoo
Joan J
JJ
Harvard Medical School, MA, USA.
Cole
Craig Emmitt
CE
Anderson
Kenneth C
KC
D000077584:2-Methoxyestradiol; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000627:therapeutic use; D003546:Cysteine Endopeptidases; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D004958:Estradiol / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D009097:Multienzyme Complexes / Q000037:antagonists & inhibitors; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000473:pathology; D010087:Oxides / Q000627:therapeutic use; D046988:Proteasome Endopeptidase Complex; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use; D014020:Tissue Extracts / Q000627:therapeutic use
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D001152:Arsenicals; D004791:Enzyme Inhibitors; D009097:Multienzyme Complexes; D010087:Oxides; D014020:Tissue Extracts; C111481:shark cartilage extract; D004958:Estradiol; D013792:Thalidomide; D000077584:2-Methoxyestradiol; D003546:Cysteine Endopeptidases; D046988:Proteasome Endopeptidase Complex; D000077237:Arsenic Trioxide